256 related articles for article (PubMed ID: 30775140)
1. Familial Melanoma: Diagnostic and Management Implications.
Rossi M; Pellegrini C; Cardelli L; Ciciarelli V; Di Nardo L; Fargnoli MC
Dermatol Pract Concept; 2019 Jan; 9(1):10-16. PubMed ID: 30775140
[TBL] [Abstract][Full Text] [Related]
2. Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families.
Potjer TP; Bollen S; Grimbergen AJEM; van Doorn R; Gruis NA; van Asperen CJ; Hes FJ; van der Stoep N;
Int J Cancer; 2019 May; 144(10):2453-2464. PubMed ID: 30414346
[TBL] [Abstract][Full Text] [Related]
3. Melanoma genetics.
Read J; Wadt KA; Hayward NK
J Med Genet; 2016 Jan; 53(1):1-14. PubMed ID: 26337759
[TBL] [Abstract][Full Text] [Related]
4. Familial Melanoma and Susceptibility Genes: A Review of the Most Common Clinical and Dermoscopic Phenotypic Aspect, Associated Malignancies and Practical Tips for Management.
Zocchi L; Lontano A; Merli M; Dika E; Nagore E; Quaglino P; Puig S; Ribero S
J Clin Med; 2021 Aug; 10(16):. PubMed ID: 34442055
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Potential Melanoma Predisposition Genes in High-Risk Brazilian Patients.
Soares de Sá BC; Moredo LF; Torrezan GT; Fidalgo F; de Araújo ÉSS; Formiga MN; Duprat JP; Carraro DM
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958811
[TBL] [Abstract][Full Text] [Related]
6. Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD,
Pastorino L; Andreotti V; Dalmasso B; Vanni I; Ciccarese G; Mandalà M; Spadola G; Pizzichetta MA; Ponti G; Tibiletti MG; Sala E; Genuardi M; Chiurazzi P; Maccanti G; Manoukian S; Sestini S; Danesi R; Zampiga V; La Starza R; Stanganelli I; Ballestrero A; Mastracci L; Grillo F; Sciallero S; Cecchi F; Tanda ET; Spagnolo F; Queirolo P; Italian Melanoma Intergroup (IMI) ; Goldstein AM; Bruno W; Ghiorzo P
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32325837
[TBL] [Abstract][Full Text] [Related]
7. Update in genetic susceptibility in melanoma.
Potrony M; Badenas C; Aguilera P; Puig-Butille JA; Carrera C; Malvehy J; Puig S
Ann Transl Med; 2015 Sep; 3(15):210. PubMed ID: 26488006
[TBL] [Abstract][Full Text] [Related]
8. Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup.
Bruno W; Dalmasso B; Barile M; Andreotti V; Elefanti L; Colombino M; Vanni I; Allavena E; Barbero F; Passoni E; Merelli B; Pellegrini S; Morgese F; Danesi R; Calò V; Bazan V; D'Elia AV; Molica C; Gensini F; Sala E; Uliana V; Soma PF; Genuardi M; Ballestrero A; Spagnolo F; Tanda E; Queirolo P; Mandalà M; Stanganelli I; Palmieri G; Menin C; ; Pastorino L; Ghiorzo P
ESMO Open; 2022 Aug; 7(4):100525. PubMed ID: 35777164
[TBL] [Abstract][Full Text] [Related]
9. Germline TERT promoter mutations are rare in familial melanoma.
Harland M; Petljak M; Robles-Espinoza CD; Ding Z; Gruis NA; van Doorn R; Pooley KA; Dunning AM; Aoude LG; Wadt KA; Gerdes AM; Brown KM; Hayward NK; Newton-Bishop JA; Adams DJ; Bishop DT
Fam Cancer; 2016 Jan; 15(1):139-44. PubMed ID: 26433962
[TBL] [Abstract][Full Text] [Related]
10. POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families.
Potrony M; Puig-Butille JA; Ribera-Sola M; Iyer V; Robles-Espinoza CD; Aguilera P; Carrera C; Malvehy J; Badenas C; Landi MT; Adams DJ; Puig S
Br J Dermatol; 2019 Jul; 181(1):105-113. PubMed ID: 30451293
[TBL] [Abstract][Full Text] [Related]
11. [Increased knowledge on familial melanoma and the underlying genetics].
Helgadottir H; Nielsen K; Höiom V
Lakartidningen; 2017 May; 114():. PubMed ID: 28485764
[TBL] [Abstract][Full Text] [Related]
12. High- and intermediate-risk susceptibility variants in melanoma families from the Mediterranean area: A multicentre cohort from the MelaNostrum Consortium.
Pellegrini C; Cardelli L; Ghiorzo P; Pastorino L; Potrony M; García-Casado Z; Elefanti L; Stefanaki I; Mastrangelo M; Necozione S; Aguilera P; Rodríguez-Hernández A; Di Nardo L; Rocco T; Del Regno L; Badenas C; Carrera C; Malvehy J; Requena C; Bañuls J; Stratigos AJ; Peris K; Menin C; Calista D; Nagore E; Puig S; Landi MT; Fargnoli MC
J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):2498-2508. PubMed ID: 37611275
[TBL] [Abstract][Full Text] [Related]
13. Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain.
Sargen MR; Calista D; Elder DE; Massi D; Chu EY; Potrony M; Pfeiffer RM; Carrera C; Aguilera P; Alos L; Puig S; Elenitsas R; Yang XR; Tucker MA; Landi MT; Goldstein AM
J Am Acad Dermatol; 2020 Sep; 83(3):860-869. PubMed ID: 32283231
[TBL] [Abstract][Full Text] [Related]
14. Genetic counselling and high-penetrance susceptibility gene analysis reveal the novel CDKN2A p.D84V (c.251A>T) mutation in melanoma-prone families from Italy.
Borroni RG; Manganoni AM; Grassi S; Grasso M; Diegoli M; Giorgianni C; Favalli V; Pavoni L; Cespa M; Arbustini E
Melanoma Res; 2017 Apr; 27(2):97-103. PubMed ID: 28060055
[TBL] [Abstract][Full Text] [Related]
15. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma.
Platz A; Hansson J; Månsson-Brahme E; Lagerlof B; Linder S; Lundqvist E; Sevigny P; Inganäs M; Ringborg U
J Natl Cancer Inst; 1997 May; 89(10):697-702. PubMed ID: 9168184
[TBL] [Abstract][Full Text] [Related]
16. Genetic testing for melanoma predisposition: current challenges.
Gerstenblith MR; Goldstein AM; Tucker MA; Fraser MC
Cancer Nurs; 2007; 30(6):452-9; quiz 462-3. PubMed ID: 18025917
[TBL] [Abstract][Full Text] [Related]
17. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.
Borg A; Sandberg T; Nilsson K; Johannsson O; Klinker M; Måsbäck A; Westerdahl J; Olsson H; Ingvar C
J Natl Cancer Inst; 2000 Aug; 92(15):1260-6. PubMed ID: 10922411
[TBL] [Abstract][Full Text] [Related]
18. Genetic susceptibility to cutaneous melanoma in southern Switzerland: role of CDKN2A, MC1R and MITF.
Mangas C; Potrony M; Mainetti C; Bianchi E; Carrozza Merlani P; Mancarella Eberhardt A; Maspoli-Postizzi E; Marazza G; Marcollo-Pini A; Pelloni F; Sessa C; Simona B; Puig-Butillé JA; Badenas C; Puig S
Br J Dermatol; 2016 Nov; 175(5):1030-1037. PubMed ID: 27473757
[TBL] [Abstract][Full Text] [Related]
19. FRAMe: Familial Risk Assessment of Melanoma-a risk prediction tool to guide CDKN2A germline mutation testing in Australian familial melanoma.
Holland EA; Lo S; Kelly B; Schmid H; Cust AE; Palmer JM; Drummond M; Hayward NK; Pritchard AL; Mann GJ
Fam Cancer; 2021 Jul; 20(3):231-239. PubMed ID: 32989607
[TBL] [Abstract][Full Text] [Related]
20. CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma.
Betti M; Aspesi A; Biasi A; Casalone E; Ferrante D; Ogliara P; Gironi LC; Giorgione R; Farinelli P; Grosso F; Libener R; Rosato S; Turchetti D; Maffè A; Casadio C; Ascoli V; Dianzani C; Colombo E; Piccolini E; Pavesi M; Miccoli S; Mirabelli D; Bracco C; Righi L; Boldorini R; Papotti M; Matullo G; Magnani C; Pasini B; Dianzani I
Cancer Lett; 2016 Aug; 378(2):120-30. PubMed ID: 27181379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
